Immune checkpoint blockade therapy for bladder cancer treatment
about
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor GrowthFrom targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.Unmasking molecular profiles of bladder cancer.Immune checkpoint inhibitors for urothelial carcinoma
P2860
Immune checkpoint blockade therapy for bladder cancer treatment
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Immune checkpoint blockade therapy for bladder cancer treatment
@ast
Immune checkpoint blockade therapy for bladder cancer treatment
@en
Immune checkpoint blockade therapy for bladder cancer treatment
@nl
type
label
Immune checkpoint blockade therapy for bladder cancer treatment
@ast
Immune checkpoint blockade therapy for bladder cancer treatment
@en
Immune checkpoint blockade therapy for bladder cancer treatment
@nl
prefLabel
Immune checkpoint blockade therapy for bladder cancer treatment
@ast
Immune checkpoint blockade therapy for bladder cancer treatment
@en
Immune checkpoint blockade therapy for bladder cancer treatment
@nl
P2860
P921
P3181
P1476
Immune checkpoint blockade therapy for bladder cancer treatment
@en
P2093
Jayoung Kim
P2860
P304
P3181
P356
10.4111/ICU.2016.57.S1.S98
P407
P433
P478
57 Suppl 1
P5008
P577
2016-06-01T00:00:00Z